LEGACY: Phase 2a Trial to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamic Effects of the Anti-EL (Endothelial Lipase) Antibody MEDI5884 in Patients With Stable Coronary Artery Disease

Christian T. Ruff,Michael J. Koren,Joseph Grimsby,Anton I Rosenbaum,Xiao Tu,Sotirios K Karathanasis,Judith Falloon,Judith Hsia,Ye Guan,James Conway,Lan-Feng Tsai,B. Timothy Hummer,Boaz Hirshberg,Julia Kuder,Sabina A. Murphy,Richard T George,Marc S. Sabatine

LEGACY: Phase 2a Trial to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamic Effects of the Anti-EL (Endothelial Lipase) Antibody MEDI5884 in Patients With Stable Coronary Artery Disease

2021

Christian T. Ruff
Michael J. Koren
Joseph Grimsby
Anton I Rosenbaum
Xiao Tu
Sotirios K Karathanasis
Judith Falloon
Judith Hsia
Ye Guan
James Conway
Lan-Feng Tsai
B. Timothy Hummer
Boaz Hirshberg
Julia Kuder
Sabina A. Murphy
Richard T George
Marc S. Sabatine

Objective: Functional HDL (high-density lipoprotein) particles that facilitate cholesterol efflux may be cardioprotective. EL (endothelial lipase) hydrolyzes phospholipids promoting catabolism of H...

Keywords:

Pharmacology
Chemistry
Cholesterol
Lipoprotein
Coronary artery disease
Efflux
Catabolism
Pharmacokinetics
Endothelial lipase
Pharmacodynamics

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations